MITIGATING TISSUE DAMAGE AND FIBROSIS VIA ANTI-LTBP4 ANTIBODY

(19)

(11)

EP 2 880 053 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	15.04.2020 Bulletin 2020/16

(45)	Mention of the grant of the patent:
	26.02.2020 Bulletin 2020/09

(21)	Application number: 13835243.0

(22)	Date of filing: 01.08.2013

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
A61P 11/00^(2006.01)
C07K 16/18^(2006.01)

A61P 21/00^(2006.01)
A61P 9/00^(2006.01)

(86)	International application number:
	PCT/US2013/053255

(87)	International publication number:
	WO 2014/039189 (13.03.2014 Gazette 2014/11)

(54)	MITIGATING TISSUE DAMAGE AND FIBROSIS VIA ANTI-LTBP4 ANTIBODY ABSCHWÄCHUNG VON GEWEBEVERLETZUNGEN UND FIBROSE DURCH ANTI-LTBP4 ANTIKÖRPER RÉDUCTION DES LÉSIONS TISSULAIRES ET DE LA FIBROSE PAR L'UTILISATION D'ANTICORPS ANTI-LTBP4

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

01.08.2012 US 201261678564 P

(43)	Date of publication of application:
	10.06.2015 Bulletin 2015/24

(60)	Divisional application:
	20152849.4

(73)	Proprietor: Ikaika Therapeutics, LLC
	Oak Park IL 60302 (US)

(72)	Inventors:
	MCNALLY, Elisabeth M. Oak Park, Illinois 60302 (US) HEYDEMANN, Ahlke Oak Park, Illinois 60304 (US) CECO, Ermelinda Chicago, Illinois 60614 (US)

(74)	Representative: Potter Clarkson
	The Belgrave Centre Talbot Street Nottingham NG1 5GG Nottingham NG1 5GG (GB)

(56)

References cited: :

WO-A2-2004/083241
US-A1- 2011 151 490

WO-A2-2012/006181

STERNER-KOCK A ET AL: "Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, PLAINVIEW, NY, US, vol. 16, no. 17, 1 September 2002 (2002-09-01), pages 2264-2273, XP001153402, ISSN: 0890-9369, DOI: 10.1101/GAD.229102
SINHA S ET AL: "Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins.", MATRIX BIOLOGZ, vol. 17, 1998, pages 529-545, XP002753412,
HEYDEMANN ET AL.: 'Latent TGF-G3-binding protein 4 modifies muscular dystrophy in mice' JOURNAL OF CLINICAL INVESTIGATION vol. 119, 01 December 2009, pages 3703 - 3712, XP055190359
BURKS ET AL.: 'Role of TGF-b signaling in inherited and acquired myopathies' SKELETAL MUSCLE vol. 1, 04 May 2011, pages 1 - 13, XP021102266

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).